Plasma gelsolin: A general prognostic marker of health

Medical Hypotheses

Volumn 78, Issue 2, 2012, Pages 203-210

  Peddada, Nagesh ^a   Sagar, Amin ^a   Ashish, ^a   Garg, Renu ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHLOROQUINE; CYTOCHALASIN D; GELSOLIN; RECOMBINANT GELSOLIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; BURN; CRITICALLY ILL PATIENT; DISEASE MARKER; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; HYPEROXIA; INJURY; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG DISEASE; LUNG INTERSTITIAL THICKENING; MALARIA FALCIPARUM; MORTALITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TICK BORNE ENCEPHALITIS;

ACTINS; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; BURNS; DISEASE PROGRESSION; GELSOLIN; HEALTH STATUS; HUMANS; HYPEROXIA; INFLAMMATION; INTENSIVE CARE UNITS; KIDNEY FAILURE, CHRONIC; MICE; PROGNOSIS; RATS; SEPSIS;

ANIMALIA;

EID: 84855191919     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.024     Document Type: Article

References (55)

1. Osborn T.M., Verdrengh M., Stossel T.P., Tarkowski A., Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R117.
2. Kwiatkowski D.J., Stossel T.P., Orkin S.H., Mole J.E., Colten H.R., Yin H.L. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 1986, 323:455-458.
3. Yin H.L., Kwiatkowski D.J., Mole J.E., Cole F.S. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 1984, 259:5271-5276.
4. Kwiatkowski D.J., Mehl R., Yin H.L. Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 1988, 106:375-384.
5. Vouyiouklis D.A., Brophy P.J. A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J Neurochem 1997, 69:995-1005.
6. Wen D., Corina K., Chow E.P., Miller S., Janmey P.A., Pepinsky R.B. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 1996, 35:9700-9709.
7. Kwiatkowski D.J., Mehl R., Izumo S., Nadal-Ginard B., Yin H.L. Muscle is the major source of plasma gelsolin. J Biol Chem 1988, 263:8239-8243.
8. Li G.H., Arora P.D., Chen Y., McCulloch C.A., Liu P. Multifunctional roles of gelsolin in health and diseases. Med Res Rev 2010.
9. Bucki R., Levental I., Kulakowska A., Janmey P.A. Plasma gelsol function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008, 9:541-551.
10. 2+ activation of full-length human plasma gelsolin. J Biol Chem 2007, 282:25884-25892.
11. Garg R., Peddada N., Sagar A., Nihalani D., Ashish Visual insight into how low ph alone can induce actin-severing ability in gelsolin under calcium-free conditions. J Biol Chem 2011, 286:20387-20397.
12. Sun H.Q., Yamamoto M., Mejillano M., Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 1999, 274:33179-33182.
13. Yin H.L., Stull J.T. Proteins that regulate dynamic actin remodeling in response to membrane signaling minireview series. J Biol Chem 1999, 274:32529-32530.
14. Lee W.M., Galbraith R.M. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992, 326:1335-1341.
15. Osborn T.M., Dahlgren C., Hartwig J.H., Stossel T.P. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 2007, 292:C1323-1330.
16. Bucki R., Kulakowska A., Byfield F.J., Zendzian-Piotrowska M., Baranowski M., Marzec M., et al. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol Cell Physiol 2010, 299:C1516-1523.
17. Lind S.E., Janmey P.A. Human plasma gelsolin binds to fibronectin. J Biol Chem 1984, 259:13262-13266.
18. Bucki R., Byfield F.J., Kulakowska A., McCormick M.E., Drozdowski W., Namiot Z., et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol 2008, 181:4936-4944.
19. Bucki R., Georges P.C., Espinassous Q., Funaki M., Pastore J.J., Chaby R., et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005, 44:9590-9597.
20. Mburu P., Romero M.R., Hilton H., Parker A., Townsend S., Kikkawa Y., et al. Gelsolin plays a role in the actin polymerization complex of hair cell stereocilia. PLoS One 2010, 5:e11627.
21. Haddad J.G., Harper K.D., Guoth M., Pietra G.G., Sanger J.W. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 1990, 87:1381-1385.
22. Erukhimov J.A., Tang Z.L., Johnson B.A., Donahoe M.P., Razzack J.A., Gibson K.F., et al. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Respir Crit Care Med 2000, 162:288-294.
23. Meier U., Gressner O., Lammert F., Gressner A.M. Gc-globulin: roles in response to injury. Clin Chem 2006, 52:1247-1253.
24. Herrmannsdoerfer A.J., Heeb G.T., Feustel P.J., Estes J.E., Keenan C.J., Minnear F.L., et al. Vascular clearance and organ uptake of G- and F-actin in the rat. Am J Physiol 1993, 265:G1071-1081.
25. Lee P.S., Sampath K., Karumanchi S.A., Tamez H., Bhan I., Isakova T., et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 2009, 20:1140-1148.
26. Rothenbach P.A., Dahl B., Schwartz J.J., O'Keefe G.E., Yamamoto M., Lee W.M., et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 2004, 96:25-31.
27. Lind S.E., Smith D.B., Janmey P.A., Stossel T.P. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 1988, 138:429-434.
28. Ito H., Kambe H., Kimura Y., Nakamura H., Hayashi E., Kishimoto T., et al. Depression of plasma gelsolin level during acute liver injury. Gastroenterology 1992, 102:1686-1692.
29. Lee P.S., Drager L.R., Stossel T.P., Moore F.D., Rogers S.O. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 2006, 243:399-403.
30. Lee P.S., Waxman A.B., Cotich K.L., Chung S.W., Perrella M.A., Stossel T.P. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007, 35:849-855.
31. Smith D.B., Janmey P.A., Sherwood J.A., Howard R.J., Lind S.E. Decreased plasma gelsolin levels in patients with plasmodium falciparum malaria: a consequence of hemolysis?. Blood 1988, 72:214-218.
32. Suhler E., Lin W., Yin H.L., Lee W.M., et al. Decreased plasma gelsolin concentrations in acute liver failure myocardial infarction and myonecrosis. Crit Care Med 1997, 25:594-598.
33. DiNubile M.J., Stossel T.P., Ljunghusen O.C., Ferrara J.L., Antin J.H. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 2002, 100:4367-4371.
34. Mounzer K.C., Moncure M., Smith Y.R., Dinubile M.J. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999, 160:1673-1681.
35. Kulakowska A., Ciccarelli N.J., Wen Q., Mroczko B., Drozdowski W., Szmitkowski M., et al. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC Neurol 2010, 10:107.
36. Christofidou-Solomidou M., Scherpereel A., Solomides C.C., Christie J.D., Stossel T.P., Goelz S., et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 2002, 50:54-60.
37. Smith D.B., Janmey P.A., Lind S.E. Circulating actin-gelsolin complexes following oleic acid-induced lung injury. Am J Pathol 1988, 130:261-267.
38. Wang H., Cheng B., Chen Q., Wu S., Lv C., Xie G., et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care 2008, 12:R106.
39. Lee P.S., Patel S.R., Christiani D.C., Bajwa E., Stossel T.P., Waxman A.B. Plasma gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS One 2008, 3:e3712.
40. Rithidech K.N., Honikel L., Milazzo M., Madigan D., Troxell R., Krupp L.B. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult Scler 2009, 15:455-464.
41. Kulakowska A., Zajkowska J.M., Ciccarelli N.J., Mroczko B., Drozdowski W., Bucki R. Depletion of plasma gelsolin in patients with tick-borne encephalitis and lyme neuroborreliosis. Neurodegener Dis 2011, 8:375-380.
42. Endres M., Fink K., Zhu J., Stagliano N.E., Bondada V., Geddes J.W., et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 1999, 103:347-354.
43. Guo X.C., Luo B.Y., Li X.F., Yang D.G., Zheng X.N., Zhang K. Plasma gelsolin levels and 1-year mortality after first-ever ischemic stroke. J Crit Care 2011.
44. Carro E. Gelsolin as therapeutic target in Alzheimer's disease. Expert Opin Ther Targets 2010, 14:585-592.
45. Chauhan V.P., Ray I., Chauhan A., Wisniewski H.M. Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 1999, 258:241-246.
46. Chauhan V., Ji L., Chauhan A. Anti-amyloidogenic anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 2008, 9:381-389.
47. Ray I., Chauhan A., Wegiel J., Chauhan V.P. Gelsolin inhibits the fibrillization of amyloid beta-protein and also defibrillizes its preformed fibrils. Brain Res 2000, 853:344-351.
48. Vargas T., Antequera D., Ugalde C., Spuch C., Carro E. Gelsolin restores A beta-induced alterations in choroid plexus epithelium. J Biomed Biotechnol 2010, 2010:805405.
49. Antequera D., Vargas T., Ugalde C., Spuch C., Molina J.A., Ferrer I., et al. Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009, 36:42-50.
50. Guntert A., Campbell J., Saleem M., O'Brien D.P., Thompson A.J., Byers H.L., et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 2010, 21:585-596.
51. Cohen T.S., Bucki R., Byfield F.J., Ciccarelli N.J., Rosenberg B., Dinubile M.J., et al. Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine 2011, 54:235-238.
52. Christofidou-Solomidou M., Scherpereel A., Solomides C.C., Muzykantov V.R., Machtay M., Albelda S.M., et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 2002, 180:91-104.
53. Matsuoka Y., Saito M., LaFrancois J., Gaynor K., Olm V., Wang L., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.
54. Hirko A.C., Meyer E.M., King M.A., Hughes J.A. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 2007, 15:1623-1629.
55. Van den Abbeele A., De Clercq S., De Ganck A., De Corte V., Van Loo B., Soror S.H., et al. A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell Mol Life Sci 2010, 67:1519-1535.